Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration

NCT03677934 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03677934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03677934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
September 12, 2018
Completion date
June 9, 2021
Enrollment
415 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration